Amatuximab (MORab-009) is a chimeric, humanized IgG1/k MAb that targets the cell surface mesothelin (MSLN). Mesothelin is a glycosylphosphatidyl inositol (GPI)-anchored membrane glycoprotein, which is present in a restricted set of normal adult tissues such as the mesothelium.

Amatuximab (MORAb-009) is a mouse-human chimeric monoclonal antibody with a selective affinity for MSLN. In vitro, amatuximab elicits antibody-dependent cellular cytotoxicity (ADCC) against mesothelin expressing tumor cell lines and inhibits heterotypic cell adhesion of mesothelin-positive tumor cells to CA125-expressing tumor cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

In tumor xenograft studies, combination treatment with amatuximab plus chemotherapy led to a greater reduction in the growth of mesothelin-expressing tumors than either Amatuximab or chemotherapy alone.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

In tumor xenograft studies, combination treatment with amatuximab plus chemotherapy led to a greater reduction in the growth of mesothelin-expressing tumors than either Amatuximab or chemotherapy alone.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

• . Hassan R, et al. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014;20(23):5927-5936.  [Content Brief]

  . Baldo P, et al. Amatuximab and novel agents targeting mesothelin for solid tumors. Onco Targets Ther. 2017;10:5337-5353. Published 2017 Nov 8.  [Content Brief]